drugset / Trial / NCT07502872
TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Phase 2
Not yet recruiting
30 enrolled
Brown University
Genentech, Inc. · collabIncyte Corporation · collabNatera, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, phase 2, open-label clinical trial of a novel combination of polatuzumab vedotin, glofitamab, and tafasitamab (TPG) as first-line treatment of patients with diffuse large B cell lymphoma (DLBCL) or high-grade B cell lymphoma (HGBL).
Timeline
- Start
- 2026-11-01
- Primary completion
- 2030-01-01
- Completion
- 2030-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Glofitamab | Monoclonal antibody | — | — |
| Subject | Polatuzumab Vedotin | Other / unclassified | — | — |
| Subject | Tafasitamab | Monoclonal antibody | — | — |
| Background | Obinutuzumab | Monoclonal antibody | — | — |